5 Results for "

cap formation

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "cap formation" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-15523
CAS No.: 351351-75-2
Purity:  99.51%
Research Areas:  

Cancer

Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15523A
CAS No.: 1177798-88-7
Purity:  99.73%
Target:  

DNA/RNA Synthesis CMV

Research Areas:  

Infection Cancer

Braco-19 trihydrochloride is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor .
loading...
    loading...
Cat. No.: HY-W996116
CAS No.: 1933460-23-1
AZM198 is an orally active myeloperoxidase (MPO) inhibitor. AZM198 irreversibly inactivates MPO (IC50=0.015 μM) via covalent binding to the heme prosthetic group, preferentially targets extracellular MPO activity, and reduces neutrophil extracellular trap formation, reactive oxygen species production and degranulation. AZM198 increases the fibrous cap thickness of atherosclerotic plaques, reduces lesion area, ameliorates hepatic steatosis and fibrosis in non-alcoholic steatohepatitis, and alleviates proteinuria and inflammatory infiltration associated with glomerulonephritis. AZM198 also decreases circulating levels of high-sensitivity Cardiac Troponin I and IL-1β, and mitigates endothelial cell injury. Therefore, AZM198 is suitable for research on various MPO-related diseases, including atherosclerotic cardiovascular disease, myocardial infarction, ischemic stroke, non-alcoholic steatohepatitis and crescentic glomerulonephritis .
loading...
    loading...
Cat. No.: HY-115693
CAS No.: 2292123-03-4
Target:  

Bacterial

Research Areas:  

Infection

CAP 3 is a cholic acid-peptide conjugate (CAP) antimicrobial agent. CAP 3 effectively inhibits Gram-negative bacteria, with MIC99 (minimum inhibitory concentration for 99% bacterial killing) values of 8 μM, 16 μM, and 16 μM against E. coli, Klebsiella pneumoniae and Acinetobacter baumannii, respectively. CAP 3 exerts its antibacterial effects by disrupting the structural integrity of the bacterial lipopolysaccharide (LPS) outer membrane. CAP 3 rapidly kills bacteria, inhibits biofilm formation, and effectively combats drug-resistant strains and persistent bacterial infections .
loading...
    loading...
Cat. No.: HY-145502
CAS No.: 384835-52-3
Research Areas:  

Others

1,2-Dipalmitoyl-sn-glycero-3-PE-N-(cap biotin) sodium is used in the composition of lipid vesicles for supported lipid bilayer (SLB) formation. 1,2-Dipalmitoyl-sn-glycero-3-PE-N-(cap biotin) sodium can be used as a probe for understanding the interactions between proteins and lipid-tethered ligands .
loading...
    loading...